Meta-analysis finds sarcopenia associated with 44% higher atrial fibrillation risk in observational dataSarcopenia linked to higher risk of atrial fibrillation in large review of studies

This systematic review and meta-analysis examined the association between sarcopenia and the risk of developing atrial fibrillation. The analysis pooled data from observational cohort studies involving 7,358,442 participants, comparing those with sarcopenia (or its components) to those without. The primary finding was that sarcopenia was significantly associated with a 44% increased risk of atrial fibrillation onset, with a pooled hazard ratio of 1.44 (95% confidence interval: 1.22–1.68). Absolute event numbers were not reported in the meta-analysis.

No safety or tolerability data specific to sarcopenia as an exposure were reported, as this analysis examined observational associations rather than an intervention. The analysis did not report on adverse events, serious adverse events, or discontinuations related to the condition.

The key limitation noted was high statistical heterogeneity among the included studies, with an I² value of 93.5%, indicating substantial variability in study results beyond chance. Funding sources and author conflicts of interest were not reported. The analysis exclusively used observational data, which can identify associations but cannot establish causality.

For clinical practice, this evidence suggests sarcopenia may serve as a marker for increased atrial fibrillation risk in the populations studied. However, the high heterogeneity and observational nature mean this association requires confirmation in more standardized studies. Clinicians should be aware of this potential link while recognizing that it does not imply sarcopenia causes atrial fibrillation or that treating sarcopenia would reduce AF risk.